Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis.

Journal of the American Academy of Dermatology 2020 Oct 31

Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis.

Related Questions

Have you seen any increased dermatologic toxicity with whole breast or chest wall radiation if patients have received recent or concurrent pembrolizumab?

New answer by Radiation Oncologist at Memorial Sloan Kettering Cancer Center (February 26, 2024)

Yan et al., PMID 33137440

Read more (3 Answers available)